Founder / systems builder
Varun Sharma
- Founder, VARUNÉ Bio and VARUNÉ Labs
- Founder, VARUNÉ Intelligence
Building the chain between medicines intelligence, scientific development and the future infrastructure required to turn evidence into accountable action.
- Glasgow-born
- British-Indian perspective
- Medicines + intelligent systems
Founder thesis
Build the chain.
Keep every link honest.
Varun's thesis is that medicines intelligence, formulation, development, manufacturing and physical infrastructure should inform one another without being presented as one finished system before the evidence exists.
His published account traces his earliest commercial education to his family's Glasgow corner shop: stock, cash, trust and poor decisions became visible quickly. The setting changed from shelves and tills to pharmaceuticals and technology; the operating test did not.
VARUNÉ Bio is the lead ingredient and formulation R&D company within the VARUNÉ portfolio, with skincare as its first commercial focus. Its current programmes address skin pigmentation, polar-associated polymers and biochemical light through molecular formulation science. VARUNÉ Labs is the separate physical science-park development programme. The Labs direction is being aligned with VARUNÉ Intelligence Ltd’s exploratory work in AI, robotics and engineering.
- 01 / Now
Define the useful scientific contribution.
Connect a specific formulation or automation question to a reviewable pathway, specialist capability and the evidence needed for the next decision.
- 02 / Next
Test the infrastructure case.
Reduce uncertainty around demand, location, operator, utilities, planning, regulation, capital and phased economics.
- 03 / Horizon
Connect capability only when justified.
Bring laboratories, automation and manufacturing together only after rights, approvals, quality systems and demand support the move.
Campus capital boundary
Every programme needs its own evidence.
Shared leadership and work in other companies do not establish a committed capital package, land right, operating capability or partnership for VARUNÉ Labs. The Glasgow and Hyderabad pathways require their own evidence.
Make the future visible. Keep the present truthful.
Concept architecture can make an ambition legible. It cannot evidence a site, approval, partner, facility or operating capability.
Connected founder work
Connected work and its current stage.
The connection shown here is founder-level and thematic. It does not collapse a company, a product, a predevelopment concept and a research direction into one legal or operating claim.
VARUNÉ Labs
A physical science-park development programme assessing future formulation, analytical and translational infrastructure, with separately gated manufacturing options.
Explore the campus thesisVARUNÉ Bio
The portfolio’s lead ingredient and formulation R&D company, with skincare as its first commercial focus. Molecular formulation science connects programmes in skin pigmentation, polar-associated polymers and biochemical light. Current work is literature synthesis and programme definition.
Explore VARUNÉ BioVARUNÉ Intelligence
Exploratory AI and robotics for complex real-world problems.
Explore VARUNÉ IntelligenceVARUNÉ Space Systems
An exploratory, precommercial direction in space systems and extreme environments.
Explore VARUNÉ Space SystemsOperating doctrine
Ambition becomes credible through gates.
The doctrine is designed to preserve ambition while protecting capital, scientific integrity and public trust.
- 01
Evidence before infrastructure
Every proposed facility should answer a defined scientific, commercial or public-value need before capital becomes irreversible.
- 02
Truth before theatre
A concept can make a possibility legible. It cannot prove land, finance, planning, licences, equipment, partners or operating readiness.
- 03
Human authority before automation
Artificial intelligence and robotics may structure evidence and extend capability; accountable people must still own regulated decisions.
- 04
Partnership before unnecessary ownership
Controlled access and specialist collaboration can be more credible than buying infrastructure before demand, quality and economics are known.
- 05
Review before mythology
Each stage should retain the evidence, decision, owner and reason to advance, change direction or stop.
Published thinking + public record
Publication is evidence of a public argument, not endorsement.
The records below are classified by what they actually are: founder commentary, a reader letter or publisher-authored coverage of a proposal.
- 01Founder commentary
Express Pharma
From capacity to capability: Five proofs for India’s pharma future
Contributed article by Varun Sharma. Read the original publication at Express Pharma.
Open publisher record - 02Founder commentary
ET Pharma
India's pharma quality reset will be won after the inspector leaves
Publisher metadata identifies Varun Sharma as the author.
Open publisher record - 03Reader letter
Financial Times
Letter: The real test is whether invention leads to adoption
Published under the current name Varun Sharma; this is a reader letter, not staff coverage.
Open publisher record - 04Publisher-authored comment
Pharmaceutical Technology
Why the India-UK trade deal now needs a five-gate implementation ledger
A comment article by Ross Law centred on a proposal from Varun Sharma; it does not establish adoption or endorsement of that proposal.
Open publisher record - 05Founder commentary
PharmaTimes
How we roll
Published under an earlier public name; the attribution is reconciled on the canonical founder biography.
Open publisher record - 06Founder commentary
Manufacturing Chemist
NICE approval is not enough: why the UK's next medicines challenge is operational delivery
The public standfirst identifies Varun Sharma as NEUVIOR's founder; subscriber access may be required.
Open publisher record - 07Founder commentary
Startups Magazine
What my dad's corner shop taught me
A first-person account published under the current name Varun Sharma.
Open publisher record - 08Founder commentary
BusinessCloud
Why neurodivergent founders can excel at building complex systems
A first-person account published under the current name Varun Sharma and explicitly connected to NEUVIOR and PHARMORIS.
Open publisher record
Identity record
One canonical public identity.
Varun Sharma
Use for biographies, titles, metadata and new communications across the founder and company record.
Earlier-name records are reconciled only on the canonical evidence-indexed biography, where source attribution requires it. Read the canonical biography.
Campus status
Glasgow and Hyderabad remain proposals under test.
The visual ambition can be expansive. The current-status language must stay precise in both regions.
Glasgow / Scotland
A medicines and intelligent-systems campus direction.
The AMIDS and Glasgow Airport corridor is an area of interest for non-binding diligence, not a selected or controlled site.
- No secured land or site agreement
- No approved campus capital or construction programme
- No planning consent, operating licence or opening date
Hyderabad / Telangana
A distinct India pathway for future scientific capability.
The Hyderabad programme remains an early feasibility and partner-pathway concept with no selected or secured location.
- No selected site, land right or lease
- No approved capital, construction or commissioning route
- No licence, operating facility, partner commitment or opening date
Questions / answered directly
The useful answers, without the mythology.
01Who is the founder of VARUNÉ Labs?
Varun Sharma is the founder of VARUNÉ Labs and leads the development of its proposed Scottish campus concept.
02How are earlier-name records reconciled?
Varun Sharma is the current canonical public name. Earlier-name records are reconciled on the canonical founder biography and described here only where accurate source attribution requires it.
03Is VARUNÉ Labs Scotland already operating?
No. It is a predevelopment proposal. No site, planning consent, committed campus capital package, construction programme, operating licence or opening date has been secured or approved.
04How does VARUNÉ Labs relate to VARUNÉ Intelligence?
VARUNÉ Labs is the physical science-park development direction being aligned with VARUNÉ Intelligence Ltd (SC857816), the portfolio’s exploratory AI, robotics and engineering company. Its campus capabilities remain proposed and subject to separate site, finance, operator and approval decisions.
05Where is the proposed campus planned?
The AMIDS and Glasgow Airport corridor is the preferred area for detailed, non-binding diligence. This is an area of interest, not a selected or controlled site.
06What is the development model?
The model begins with partner access and evidence. Internal facilities would be considered only when demand, quality, governance, economics and strategic value support the commitment.
07Does VARUNÉ Labs have partnerships with organisations named on this site?
No relationship should be inferred from a contextual reference. Any partnership would be described only after written agreement and permission to publish it.
08Does the publication record mean the outlets endorse VARUNÉ Labs?
No. The records include founder commentary, a reader letter and publisher-authored coverage of a proposal. Publication does not establish endorsement, partnership, investment, adoption or support for VARUNÉ Labs.
09How does VARUNÉ Labs relate to the wider portfolio?
VARUNÉ Labs is a physical science-park predevelopment programme being aligned with VARUNÉ Intelligence Ltd (SC857816). VARUNÉ Bio, the public name of VARUNÉ BIOSYSTEMS LTD (16820832), is the portfolio’s lead ingredient and formulation R&D company. Its research is separate from the physical Labs development programme, and Bio does not occupy an operating Labs facility. VARUNÉ Group is the founder-led portfolio brand. Shared leadership does not establish company ownership or campus occupancy.
10Is the Hyderabad campus operating?
No. The Hyderabad pathway remains a predevelopment concept. The site does not claim a selected or secured site, land right, committed campus capital, planning approval, construction, operating licences, commissioned laboratories, partner commitment or an opening date.
Source record
Identity, entity and relationship evidence.
Owned profiles, public registers and funding records have different evidential weight. Each source is labelled by what it can and cannot support.
- 01VARUNÉ INTELLIGENCE LTD: Companies House
Active company SC857816, incorporated on 4 August 2025. Current registered office and company details checked on 30 September 2026. Registration does not prove an operating science campus.
- 02Varun Sharma: canonical founder biography
The evidence-indexed personal record for current identity, roles, publisher-written and project coverage, authored commentary, company material and future ambition.
- 03Varun Sharma: canonical LinkedIn profile
The designated professional profile. It is a self-authored identity source, not independent coverage.
- 04Founder: UKRI Gateway to Research
Publicly records the founder under an earlier name and associates that record with the PHARMORIS and VIONIX ZERO funded projects. This page does not derive company-wide support, contribution or cash-receipt totals.
- 05VARUNÉ SPACE SYSTEMS LTD filing history: Companies House
Records VARUNÉ SPACE SYSTEMS LTD as the current name from 1 September 2026. VYRONIS TECHNOLOGIES LTD is a historical name of the same company, not a current venture name.
Follow the work as it earns the next gate